Alto Capital

Alto Neuroscience is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to psychiatry. By leveraging its proprietary Precision Psychiatry Platform, the company analyzes brain-based biomarkers—including EEG, behavioral tasks, and wearable data—to identify patient subpopulations most likely to respond to its drug candidates. Alto's lead programs, ALTO-100 and ALTO-300, are currently in Phase 2b trials for major depressive disorder, targeting patients identified by specific cognitive and electroencephalogram biomarkers. The company's goal is to replace the current trial-and-error treatment model in mental health with data-driven, personalized therapies.